Aptorum Group Ltd Class A (APM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Aptorum Group Ltd Class A (APM) has a cash flow conversion efficiency ratio of -0.039x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-535.72K) by net assets ($13.79 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Aptorum Group Ltd Class A for the company's overall valuation and market capitalisation.
Aptorum Group Ltd Class A - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Aptorum Group Ltd Class A's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Aptorum Group Ltd Class A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aptorum Group Ltd Class A ranked by their cash flow conversion efficiency. Explore Aptorum Group Ltd Class A earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CML Microsystems Plc
LSE:CML
|
0.030x |
|
IMMUTABLE HOLDINGS INC.
F:B8X0
|
-0.142x |
|
Ireka Corporation Bhd
KLSE:8834
|
0.003x |
|
MEDICOX Co. Ltd
KQ:054180
|
-0.040x |
|
SDCL EDGE Acquisition Corporation
NYSE:SEDA
|
-0.009x |
|
Ilika plc
LSE:IKA
|
-0.077x |
|
Founder Group Limited Ordinary Shares
NASDAQ:FGL
|
-0.841x |
|
Ecoclime Group AB Series B
ST:ECC-B
|
0.000x |
Annual Cash Flow Conversion Efficiency for Aptorum Group Ltd Class A (2016–2025)
The table below shows the annual cash flow conversion efficiency of Aptorum Group Ltd Class A from 2016 to 2025. View APM stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $13.79 Million | $-1.84 Million | -0.133x | -31.63% |
| 2024-12-31 | $11.78 Million | $-1.19 Million | -0.101x | +79.86% |
| 2023-12-31 | $15.38 Million | $-7.72 Million | -0.502x | +68.07% |
| 2022-12-31 | $7.83 Million | $-12.32 Million | -1.573x | -87.90% |
| 2021-12-31 | $17.51 Million | $-14.65 Million | -0.837x | -100.42% |
| 2020-12-31 | $38.15 Million | $-15.93 Million | -0.418x | +53.66% |
| 2019-12-31 | $14.85 Million | $-13.38 Million | -0.901x | -194.02% |
| 2018-12-31 | $32.75 Million | $-10.04 Million | -0.306x | -60.21% |
| 2017-12-31 | $30.23 Million | $-5.78 Million | -0.191x | -74.34% |
| 2016-12-31 | $25.11 Million | $-2.76 Million | -0.110x | -- |
About Aptorum Group Ltd Class A
Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small mol… Read more